Eli Lilly and Company (NYSE:LLY) Shares Acquired by Lantz Financial LLC

Lantz Financial LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,110 shares of the company’s stock after acquiring an additional 94 shares during the quarter. Lantz Financial LLC’s holdings in Eli Lilly and Company were worth $521,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of LLY. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company in the first quarter valued at $25,000. Bogart Wealth LLC increased its stake in shares of Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after purchasing an additional 58 shares during the period. Laffer Tengler Investments bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $33,000. Raleigh Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 156.4% during the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares during the period. Finally, Tanglewood Legacy Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $37,000. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 591 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $466.62, for a total value of $275,772.42. Following the transaction, the insider now owns 101,028,219 shares in the company, valued at $47,141,787,549.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 591 shares of the company’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $466.62, for a total transaction of $275,772.42. Following the completion of the sale, the insider now owns 101,028,219 shares of the company’s stock, valued at $47,141,787,549.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 976,153 shares of company stock worth $21,080,192,113. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. Truist Financial increased their target price on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Citigroup upped their price target on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Argus raised their price objective on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Finally, Credit Suisse Group upped their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Stock Up 0.6 %

Eli Lilly and Company stock traded up $3.36 during mid-day trading on Tuesday, hitting $574.64. The company’s stock had a trading volume of 235,420 shares, compared to its average volume of 3,021,886. Eli Lilly and Company has a 52-week low of $296.32 and a 52-week high of $601.84. The company has a market cap of $545.50 billion, a PE ratio of 79.44, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The firm’s 50 day moving average is $512.56 and its 200 day moving average is $439.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same period in the prior year, the firm earned $1.25 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.